Antibodies to EpCAM have been developed for cancer therapy, either as a native monoclonal agent, anti-EpCAM toxin-conjugated antibody, or IL2-conjugated antibody that exhibit promising clinical activity [60]. This evidence concerns the gene EPCAM and cancer.